NasdaqGM:GPCRPharmaceuticals
Genentech Licensing Deal and Guggenheim Reaffirmation Could Be A Game Changer For Structure Therapeutics (GPCR)
Earlier in January 2026, Guggenheim reaffirmed its positive view on Structure Therapeutics, pointing to increased confidence in its oral obesity drug aleniglipron and progress on the early-stage candidate ACCG-2671.
Guggenheim also highlighted Structure Therapeutics’ licensing deal with Genentech, which includes a US$100,000,000 upfront payment and potential royalties, underscoring external validation of its pipeline.
Next, we’ll examine how Guggenheim’s confidence in aleniglipron’s...